Double-Blind, Placebo-Controlled Trial of Risperidone Plus Amantadine in Children With Autism

Mohammadi, Mohammad-Reza; Yadegari, Nourrollah; Hassanzadeh, Elmira; Farokhnia, Mehdi; Yekehtaz, Habibeh; Mirshafiee, Omid; Akhondzadeh, Shahin

doi:10.1097/wnf.0b013e3182a9339d

Cited by 45 publications

(20 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two drugs, pentoxylline (phosphodiesterase inhibitor) and amantadine (NMDA antagonist), have been tested in clinical trials of ASD as combination treatment with risperidone. Both showed effectiveness in ameliorating behavioral problems 78,79 . Another drug loxapine, a typical anti-psychotic, was effectiveness as an add-on therapy for irritability in ASD 80 .…”

Section: Autistic Spectrum Disordersmentioning

confidence: 99%

When GWAS meets the Connectivity Map: drug repositioning for seven psychiatric disorders

Chau

Chiu

et al. 2016

Preprint

View full text Add to dashboard Cite

Our knowledge of disease genetics has advanced rapidly during the past decade, with the advent of high-throughput genotyping technologies such as genome-wide association studies (GWAS). However, few methodologies were developed and systemic studies performed to identify novel drug candidates utilizing GWAS data. In this study we focus on drug repositioning, which is a cost-effective approach to shorten the developmental process of new therapies. We proposed a novel framework of drug repositioning by comparing GWAS-imputed transcriptome with drug expression profiles from the Connectivity Map. The approach was applied to 7 psychiatric disorders. We discovered a number of novel repositioning candidates, many of which are supported by preclinical or clinical evidence. We found that the predicted drugs are significantly enriched for known psychiatric medications, or therapies considered in clinical trials. For example, drugs repurposed for schizophrenia are strongly enriched for antipsychotics (p = 4.69E-06), while those repurposed for bipolar disorder are enriched for antipsychotics (p = 2.26E-07) and antidepressants (p = 1.17E-05).These findings provide support to the usefulness of GWAS signals in guiding drug discoveries and the validity of our approach in drug repositioning. We also present manually curated lists of top repositioning candidates for each disorder, which we believe will serve as a useful resource for researchers.

show abstract

Section: Autistic Spectrum Disordersmentioning

confidence: 99%

When GWAS meets the Connectivity Map: drug repositioning for seven psychiatric disorders

Chau

Chiu

et al. 2016

Preprint

View full text Add to dashboard Cite

show abstract

“…In fact, this tool evaluates five categories of behavioral abnormalities, three of which are core deficits in AD (lethargy/social withdrawal, stereotypic behavior, and inappropriate speech) and the remaining two address associated disturbances (irritability and hyperactivity/noncompliance). Reliability and content validity of this tool has been already used in several studies in Iran (Hasanzadeh et al, 2012;Ghaleiha et al 2013a;Ghaleiha et al 2013b;Mohammadi et al, 2013;Nikoo et al, 2015).…”

Section: Discussionmentioning

confidence: 99%

A pilot double-blind placebo-controlled trial of pioglitazone as adjunctive treatment to risperidone: Effects on aberrant behavior in children with autism

Ghaleiha¹,

Rasa²,

Nikoo³

et al. 2015

Psychiatry Research

Self Cite

View full text Add to dashboard Cite

“…A total of 6 out of 51 randomized controlled trials met the eligibility criteria (n = 231, mean age = 8.25 years) [3][4][5][6][7][8][9] (Table 1 Effects of augmentation agents in autistic disorder patients treated with risperidone: a systematic review and a metaanalysis…”

Section: Letter To the Editorsmentioning

confidence: 99%

Effects of augmentation agents in autistic disorder patients treated with risperidone: a systematic review and a meta-analysis

Soares¹,

Shiozawa²,

Trevizol³

et al. 2016

Trends Psychiatry Psychother.

View full text Add to dashboard Cite

Double-Blind, Placebo-Controlled Trial of Risperidone Plus Amantadine in Children With Autism

Abstract: The present study suggests that amantadine may be a potential adjunctive treatment strategy for autism and it was generally well tolerated.

Cited by 45 publications

References 8 publications

When GWAS meets the Connectivity Map: drug repositioning for seven psychiatric disorders

When GWAS meets the Connectivity Map: drug repositioning for seven psychiatric disorders

A pilot double-blind placebo-controlled trial of pioglitazone as adjunctive treatment to risperidone: Effects on aberrant behavior in children with autism

Effects of augmentation agents in autistic disorder patients treated with risperidone: a systematic review and a meta-analysis

Contact Info

Product

Resources

About